NBIX Neurocrine Biosciences Loading... : Bullish and Bearish Analyst Opinions
Loading chart...
Top Calls
Feed
23:51
Aug 17
Aug 17
Profitable company succeeding in a tough space.
Although neurological issues are a tough space, the company is profitable and does a good job with its formulations.
MED
13:05
Aug 17
Aug 17
Shares options positioning net conviction data.
Shares options positioning data showing net conviction based on fund holdings, no directional view.
MED
12:56
Aug 17
Aug 17
Reports heaviest selling across specialist funds
"Reports net conviction laggards with heaviest genuine selling across specialist funds in Q2 2026, no directional view."
MED
12:01
Aug 17
Aug 17
Reports Q2 net conviction from specialist funds
Reports Q2 net conviction chart based on 13F filings from specialist funds.
MED
13:38
Aug 12
Aug 12
The author questions the parent's prior short thesis on NBIX tied to Vykat.
The author questions the parent's prior short thesis on NBIX tied to Vykat, without stating their own position or forward view.
LOW
01:26
Apr 07
Apr 07
Neurocrine's acquisition of Soleno adds a promising late-stage asset.
Neurocrine's acquisition of Soleno adds a promising late-stage asset, providing strategic long-term growth for NBIX.
MED
About NBIX Analyst Coverage
Buzzberg tracks NBIX (Neurocrine Biosciences) across 3 sources. 2 bullish vs 0 bearish calls from 3 analysts. Sentiment: predominantly bullish (33%). 6 total trade ideas tracked. Latest voices: Jim Cramer, seedy19tron, BarbarianCap.